drugset / Trial / NCT00329082
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
RandomizedParallel-groupTriple-blindTreatment
Summary
To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.
Timeline
- Start
- 2006-05
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solanezumab | Protein / enzyme biologic | 100 mg | Intravenous |
| Subject | Solanezumab | Protein / enzyme biologic | 400 mg | Intravenous |